PURPOSE: The aim of this study was to evaluate the efficacy of Mentha crispa in the treatment of women with Trichomonas vaginalis infection (TVI). METHODS: This was a randomized, double-blind, and controlled clinical trial consisting of three phases, pre-treatment, treatment, and post-treatment. Sixty female patients were randomized to a treatment group, M. crispa (24 mg) or secnidazole (2,000 mg), both consisting of single dose. RESULTS: After treatment the proportion of patients without TVI in secnidazole group was 96.6% and in the M. crispa group was 90%, no difference was found between groups (P = 0.6120). We observed improvement in vaginal discharge, malodorous vaginal secretion, dyspareunia, dysuria, pelvic pain, and burning and itching in the genital area in patients of both groups of treatment, with no statistically significant differences between them (P > 0.05). Adverse effects were significantly higher (P = 0.0006) in the secnidazole group (66.6%) than in the M. crispa group (20%), that being mostly nausea and metallic taste with statistically significant differences between treatment groups (P < 0.001). CONCLUSION: This study is the first to show that M. crispa is effective and safe, representing an alternative for the treatment of TVI in women.
RCT Entities:
PURPOSE: The aim of this study was to evaluate the efficacy of Mentha crispa in the treatment of women with Trichomonas vaginalis infection (TVI). METHODS: This was a randomized, double-blind, and controlled clinical trial consisting of three phases, pre-treatment, treatment, and post-treatment. Sixty female patients were randomized to a treatment group, M. crispa (24 mg) or secnidazole (2,000 mg), both consisting of single dose. RESULTS: After treatment the proportion of patients without TVI in secnidazole group was 96.6% and in the M. crispa group was 90%, no difference was found between groups (P = 0.6120). We observed improvement in vaginal discharge, malodorous vaginal secretion, dyspareunia, dysuria, pelvic pain, and burning and itching in the genital area in patients of both groups of treatment, with no statistically significant differences between them (P > 0.05). Adverse effects were significantly higher (P = 0.0006) in the secnidazole group (66.6%) than in the M. crispa group (20%), that being mostly nausea and metallic taste with statistically significant differences between treatment groups (P < 0.001). CONCLUSION: This study is the first to show that M. crispa is effective and safe, representing an alternative for the treatment of TVI in women.
Authors: Elissa Meites; Charlotte A Gaydos; Marcia M Hobbs; Patricia Kissinger; Paul Nyirjesy; Jane R Schwebke; W Evan Secor; Jack D Sobel; Kimberly A Workowski Journal: Clin Infect Dis Date: 2015-12-15 Impact factor: 9.079
Authors: Thiago José Matos-Rocha; Marília Gabriela dos Santos Cavalcanti; Dyana Leal Veras; Ana Paula Sampaio Feitosa; Gabriel Gazzoni Araújo Gonçalves; Nairomberg Cavalcanti Portela-Junior; Ana Silvia Suassuna Carneiro Lúcio; Anekécia Lauro da Silva; Rafael José Ribeiro Padilha; Márcia Ortiz Mayo Marques; José Maria Barbosa-Filho; Luiz Carlos Alves; Fábio André Brayner Journal: Rev Inst Med Trop Sao Paulo Date: 2016-02-23 Impact factor: 1.846
Authors: Christina C Tam; Kevin Nguyen; Daniel Nguyen; Sabrina Hamada; Okhun Kwon; Irene Kuang; Steven Gong; Sydney Escobar; Max Liu; Jihwan Kim; Tiffany Hou; Justin Tam; Luisa W Cheng; Jong H Kim; Kirkwood M Land; Mendel Friedman Journal: BMC Complement Med Ther Date: 2021-09-13